Influenza Vaccines for the Future
Top Cited Papers
- 18 November 2010
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (21) , 2036-2044
- https://doi.org/10.1056/nejmra1002842
Abstract
Each year, seasonal epidemics of influenza cause serious illness and death throughout the world. In the United States, the annual burden of disease is estimated to be 25 million to 50 million cases of influenza, resulting in an average of 225,000 hospitalizations. Over the past three decades, the estimated number of influenza-associated deaths per year in the United States has ranged from 3349 to 48,614. The majority of deaths (>90%) occur among elderly persons, usually those with chronic underlying health conditions.1-3 The World Health Organization uses these estimates to extrapolate a likely global disease burden from influenza of up to 1 billion infections, 3 million to 5 million cases of severe disease, and between 300,000 and 500,000 deaths annually.1 Pandemics of influenza with varying rates of illness and death have occurred throughout history; the most notable was the 1918–1919 pandemic, which claimed an estimated 50 million to 100 million lives worldwide.4Keywords
This publication has 52 references indexed in Scilit:
- Induction of Broadly Neutralizing H1N1 Influenza Antibodies by VaccinationScience, 2010
- Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-Term Sterilizing Immunity against Heterologous ChallengeJournal of Virology, 2010
- Newcastle Disease Virus-Vectored Vaccines Expressing the Hemagglutinin or Neuraminidase Protein of H5N1 Highly Pathogenic Avian Influenza Virus Protect against Virus Challenge in MonkeysJournal of Virology, 2010
- Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humansVaccine, 2009
- Structural and functional bases for broad-spectrum neutralization of avian and human influenza A virusesNature Structural & Molecular Biology, 2009
- Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsVaccine, 2007
- Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza VaccineJAMA, 2007
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences, 2000
- A VIRUS OBTAINED FROM INFLUENZA PATIENTSThe Lancet, 1933